8legs: Gyre therapeutics, inc.

#1 out of 1

Gyre Therapeutics to present CG923308 data; expects IND submission Q1 2027

Gyre Therapeutics to present CG923308 preclinical data at a Shanghai conference, highlighting pipeline and strategy.
CG923308 is a CDK2–cyclin E degrader with activity across multiple preclinical models.
Oral bioavailability and tumor growth inhibition observed in preclinical studies.
Combined Gyre–Cullgen strategy aims to speed up China-focused discovery and commercialization.
IND submission for CG923308 is anticipated in Q1 2027.
The information originates from an Exhibit 99.1 slide deck used at a Shanghai conference.
TradingView summarized the company’s plans and data for the CG923308 program.
The report notes the data include oral bioavailability across species and tolerability in models.
The News is described as AI-powered but advises verification with the source.

Vote 0